Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer

Oncologist

Volumn 9, Issue 5, 2004, Pages 497-506

  Mouridsen, H ^a   Chaudri Ross, Hilary A ^b  

^a Rigshospitalet   (Denmark)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Advanced breast cancer; Aromatase inhibitors; Elderly; Letrozole; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 4944261201     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-5-497     Document Type: Article

References (14)

1. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23.
2. Kimmick GG, Balducci L. Breast cancer and aging: clinical interactions. Hematol Oncol Clin North Am 2000;14:213-234.
3. Alghanem AA, Hussain S. The effect of age on estrogen and progesterone receptor in primary breast cancer. J Surg Oncol 1985;30:29-32.
4. Elwood JM, Godolphin W. Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients. Br J Cancer 1980;42:635-644.
5. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-2606.
6. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-3757.
7. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
8. Ragaz J. Status of aromatase inhibitors in relation to other breast cancer treatment modalities. Endocr Relat Cancer 1999;6:277-291.
9. Mouridsen H, Chaudri-Ross HA. Correspondence. J Clin Oncol 2002;20:877-8.
10. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109.
11. Lipton A, Mouridsen H, Ali S et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Breast Cancer Res Treat 2001;69:210.
12. Suhail A, Leitzel K, Demers L et al. Predictive factors and response to letrozole vs tamoxifen. Accepted for presentation at 25th San Antonio Breast Cancer Symposium, San Antonio, Dec 11-14, 2002.
13. Data on file. Novartis Pharma AG, Basel, Switzerland.
14. Pfister CU, Martoni A, Zamagni C et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001;22:191-197.